Premium
Treatment of phenylketonuria using minicircle‐based naked‐DNA gene transfer to murine liver
Author(s) -
Viecelli Hiu Man,
Harbottle Richard P.,
Wong Suet Ping,
Schlegel Andrea,
Chuah Marinee K.,
VandenDriessche Thierry,
Harding Cary O.,
Thöny Beat
Publication year - 2014
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.27104
Subject(s) - phenylalanine hydroxylase , biology , minicircle , transgene , naked dna , microbiology and biotechnology , lobules of liver , genetic enhancement , gene , complementary dna , genetics , endocrinology , phenylalanine , amino acid
Host immune response to viral vectors, persistence of nonintegrating vectors, and sustained transgene expression are among the major challenges in gene therapy. To overcome these hurdles, we successfully used minicircle (MC) naked‐DNA vectors devoid of any viral or bacterial sequences for the long‐term treatment of murine phenylketonuria, a model for a genetic liver defect. MC‐DNA vectors expressed the murine phenylalanine hydroxylase ( Pah ) complementary DNA (cDNA) from a liver‐specific promoter coupled to a de novo designed hepatocyte‐specific regulatory element, designated P3, which is a cluster of evolutionary conserved transcription factor binding sites. MC‐DNA vectors were subsequently delivered to the liver by a single hydrodynamic tail vein (HTV) injection. The MC‐DNA vector normalized blood phenylalanine concomitant with reversion of hypopigmentation in a dose‐dependent manner for more than 1 year, whereas the corresponding parental plasmid did not result in any phenylalanine clearance. MC vectors persisted in an episomal state in the liver consistent with sustained transgene expression and hepatic PAH enzyme activity without any apparent adverse effects. Moreover, 14‐20% of all hepatocytes expressed transgenic PAH, and the expression was observed exclusively in the liver and predominately around pericentral areas of the hepatic lobule, while there was no transgene expression in periportal areas. Conclusion : This study demonstrates that MC technology offers an improved safety profile and has the potential for the genetic treatment of liver diseases. (H epatology 2014;60:1035–1043)